الفهرس 
Title : A pharmaceutical study on a sparingly soluble drug
ContentsOnly 14 pages are availabe for public view
 |  | from | 330 |  |  |
| | | from | 330 | | |
Abstract
Enhancement of solubility, dissolution rate and bioavailability is a challenging mission in drug development, more than 70% of the new chemical entities currently being discovered are poorly water soluble drugs. Aqueous solubility of any therapeutically active substance is a key properly as it governs dissolution, absorption and thus the in vivo efficacy. Diacerein (DCN) used in the treatment of osteoarthritis (OA). DCN is an anthraquinone derivative that has been shown to inhibit the production of interleukin-1 (IL-1) and reduce cartilage breakdown and the development of cartilage lesions in preclinical models of OA. DCN has a history of low bioavailability (35%-56%) which is attributed to poor dissolution. Over the last few years, various approaches aimed to enhance DCN solubility include complexation and solid lipid nanoparticles. The aim of work in this thesis is to increase the solubility and bioavailability using DCN as a model of poorly water soluble drug and form a novel formulation as orodispersible tablet (ODT)